Lupin launches generic Axiron topical solution in US
New Delhi: Drug firm Lupin said it has launched its testosterone topical solution in the American market.
The company has launched Testosterone Topical Solution, 30 mg per actuation, in the US after receiving approval from the United States Food and Drug Administration (USFDA), Lupin said in a filing to BSE.
The company’s product is the generic version of Eli Lilly and the company’s Axiron topical solution, 30 mg per actuation, it added.
It is indicated for replacement therapy in males for conditions associated with deficiency or absence of endogenous testosterone, Lupin said.
As per IQVIA MAT December 2017 data, testosterone topical solution, 30 mg per actuation had annual sales of approximately $179 million in the US, it added.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd